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Abstract
Background Steroid resistant nephrotic syndrome (SRNS) is a frequent cause of end stage renal disease in children and 
post-transplant disease recurrence is a major cause of graft loss.
Methods We identified all children with SRNS who underwent renal transplantation in Italy, between 2005 and 2017. Data 
were retrospectively collected for the presence of a causative gene mutation, sex, histology, duration of pre-transplant dialysis, 
age at onset and transplant, HLA matching, recurrence, therapy for recurrence, and graft survival.
Results 101 patients underwent a first and 22 a second renal transplant. After a median follow-up of 58.5 months, the dis-
ease recurred on the first renal transplant in 53.3% of patients with a non-genetic and none with a genetic SRNS. Age at 
transplant > 9 years and the presence of at least one HLA-AB match were independent risk factors for recurrence. Duration 
of dialysis was longer in children with relapse, but did not reach statistical significance. Overall, 24% of patients lost the 
first graft, with recurrence representing the commonest cause. Among 22 patients who underwent a second transplant, 5 
suffered of SRNS recurrence. SRNS relapsed in 5/9 (55%) patients with disease recurrence in their first transplant and 2 of 
them lost the second graft.
Conclusions Absence of a causative mutation represents the major risk factor for post-transplant recurrence in children with 
SRNS, while transplant can be curative in genetic SRNS. A prolonged time spent on dialysis before transplantation has no 
protective effect on the risk of relapse and should not be encouraged. Retransplantation represents a second chance after 
graft loss for recurrence.
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Introduction
Steroid resistant nephrotic syndrome (SRNS) is the most 
common acquired cause of end stage renal failure (ESRD) 
requiring transplantation in children. Advances in genetic 
screening have allowed the identification of a monogenic 
cause of SRNS in one-third of cases [1]. Genetic SRNS are 
associated with an underlying mutations in genes encod-
ing podocyte associated proteins, resulting in structural 
or functional disruption of the glomerular filtration bar-
rier [2]. The pathophysiology of SRNS without underly-
ing mutations remains poorly explained and is thought to 
involve an unknown circulating permeability factor [3] 
which may also be implicated in the recurrence soon after 
transplantation [4].
Unfortunately, in up to 50% of patients, SRNS relapses 
after transplantation and disease recurrence is a major 
cause of graft loss [4–6]. Genetic SRNS have been 
reported to have a low rate of recurrences [7–9]. On the 
other hand, previous studies have suggested non-African 
race, rapid progression to ESRD (< 3 years) and previ-
ous recurrence after transplantation to be associated with 
SRNS relapse [8, 10, 11], but no established risk factors 
can actually predict the outcome. A longer time on dialysis 
before transplantation was believed to decrease the risk of 
relapse, but not confirmed by large reports [12, 13].
There is currently little consensus regarding the best 
management of post-transplant SRNS recurrence, which 
represents a devastating complication for families and phy-
sicians, and poses a significant threat to allograft survival. 
Plasma exchange (PE), steroids and rituximab are the most 
common strategies to treat the recurrence [14].
The objective of this study was to identify factors 
affecting the risk of recurrence and graft loss in children 
with SRNS, by stratifying the population according to 
their genetic status.
Methods
We performed a retrospective, multicentre, observational 
cohort study to address the long-term prognosis of renal 
graft, the risk factors for recurrence and the predictors 
for response to therapy following recurrence in paediat-
ric patients undergoing renal transplantation because of 
a SRNS.
We identified patients who underwent renal trans-
plantation at all five Italian paediatric transplant centres, 
between 2005 and 2017, with a primary diagnosis of 
SRNS and onset before 18 years. Patients were included 
if a clinical diagnosis of SRNS was made in an individual 
with otherwise unexplained nephrotic-range proteinuria 
refractory to standard steroid therapy and subsequently 
confirmed by renal biopsy showing a histological picture 
of focal segmental glomerulosclerosis (FSGS), minimal 
change disease (MCD), or diffuse mesangial sclerosis 
(DMS). Clinical records, pathology reports and genetic 
screening results were reviewed for the purposes of this 
study. Data were also collected about sex, age of disease 
onset, duration of pre-transplant dialysis, age at transplant, 
immunosuppression, allograft donor characteristics, dis-
ease recurrence, therapy for recurrence, and graft survival.
Patients were divided in three groups: Group A (Genetic 
SRNS): patients with an identified causative genetic muta-
tion and/or a first degree relative with SRNS and/or extra-
renal disease manifestations pathognomonic of SRNS, 
Group B (Idiopathic SRNS): patients with a negative or 
heterozygous recessive genetic test result and without a first 
degree family history or associated extra-renal manifesta-
tions pathognomonic of SRNS, Group C (unknown genetic 
status): patients with no genetic analysis performed and no 
family history or extra-renal manifestations typical of SRNS.
Definitions
Nephrotic-range proteinuria, urine protein:creatinine ratio 
(uPr/uCr) ≥ 2 mg/mg. Age at disease onset, age at first clini-
cal presentation of nephrotic syndrome. Steroid resistance, 
persistence of nephrotic range proteinuria following 4 weeks 
of daily 60 mg/sqm prednisone therapy. Post-transplant 
disease recurrence, an otherwise unexplained persistent 
nephrotic range proteinuria after renal transplantation, when 
rejection was excluded. Graft loss, functional failure of the 
renal allograft, necessitating renal replacement therapy. 
Remission after recurrence, complete resolution of protein-
uria (uPr/uCr < 0.2 mg/mg). Partial remission after recur-
rence, persistent reduction of proteinuria (uPr/uCr < 2 mg/
mg) with preserved renal function.
Statistical analysis
Categorical variables were compared using the Chi squared 
test for independence. The distribution of continuous vari-
ables in groups was compared using the Wilcoxon signed-
rank test and the Kruskal–Wallis test. Linear regression 
models were used to compare continuous variables. For 
multivariate analysis, multiple logistic regression models 
were used. A p value < 0.05 was considered statistically sig-
nificant. All statistical analyses were performed using the 
open source software R. (R Core Team, 2014. R: A language 
and environment for statistical computing, R Foundation for 
Statistical Computing, Vienna, Austria).




During the study period, a total of 728 (618 deceased 
and 110 living donors) renal grafts were performed at 
the 5 Italians pediatric transplant centres, of whom 123 
in patients with ESRD secondary to SRNS. 101 patients 
received a first renal allograft and 22 a second renal trans-
plant (12 failures of the original cohort and 10 failures of 
a first transplant that occurred before the study period). 
The number of patients who received a first transplant at 
each center is as follows: Istituto G. Gaslini, Genova—31, 
Bambino Gesù Children’s Hospital, IRCCS, Rome—23, 
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore, 
Milan—20, Regina Margherita Children’s Hospital, 
Turin—15, University Hospital of Padua—12. The study 
cohort is summarized in Fig. 1.
First renal graft
101 patients (52.5% males) underwent a first renal trans-
plant. The median age at onset was 2.8 years of age (range 
0–17.2); 24 individuals (25.2%) presented with congenital 
SRNS, defined as onset of disease within the first 3 months 
of life. Renal histology was consistent with FSGS in 85 
cases, MCD in 14 and DMS in 2. Main demographic and 
clinical characteristics are summarized in Table 1. At trans-
plant all patients received an induction therapy with basi-
liximab and immunosuppression with steroids, calcineurin 
inhibitors and mofetil mycophenolate. Two patients were 
treated with plasmapheresis pre-transplantation.
Genetic testing results were available for 76 individuals 
(75.2%) (Table 2): 39 had an autosomal dominant mutation 
or were homozygous for a recessive mutation, 8 were hete-
rozygous carriers and 29 had a negative genetic test. Genetic 
results were unavailable for 25 patients, among whom we 
were able to identify 2 additional patients with genetic 
SRNS: one had a sibling with established genetic SRNS 
and another showed extra-renal disease manifestations 
Fig. 1  Study cohort
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suggesting a genetic disease. The patient cohort was there-
fore comprised of: Group A (genetic SRNS): 41 individu-
als (40.6%), Group B (idiopathic SRNS): 37 individuals 
(36.6%), and Group C (unknown genetic status): 23 indi-
viduals (22.8%). Age at the onset was similar between Group 
B (idiopathic) and Group C (unknown), while it was younger 
for patients with a genetic disease (Group A) (p < 0.0001).
NPHS1, encoding nephrin, was the single most com-
monly mutated gene and accounted for one-third (33.3%) of 
positive genetic results, followed by WT1, encoding Wilms 
tumour protein and NPHS2, encoding podocin. Mutations in 
these genes were responsible of 28.2% and 20.5% of genetic 
SRNS, respectively. Taken together, mutations in NPHS1, 
NPHS2, and WT1 accounted for 82% of identified genetic 
cases. Pathogenetic mutations were also identified in the 
following genes: PLCE1, ACTN4, COL4A5, SMARCAL1, 
LMX1B, COQ2 (Table 2). In eight cases renal disease 
was associated with a syndromic presentation, as follows: 
Denys Drash syndrome in four cases and one case each of 
Frasier syndrome, WAGR syndrome, Leopard syndrome and 
Schimke immuno-osseous dysplasia.
Post‑transplant disease recurrence
Median follow-up is 58.5 months (range 0.7–157.8). SRNS 
recurred in 32 individuals (31.7%) after the first renal trans-
plant, at a median time of 2 days post-transplantation. When 
stratified by genetic status, the incidence of post-transplant 
Table 1  Main demographic and 
clinical characteristics of SRNS 
children transplanted between 
2005 and 2017
Characteristics First renal Tx Second renal Tx
Total 101 22
Gender
 Male 53 (52.5%) 13 (59.1%)
 Female 48 (47.5%) 9 (40.9%)
Genetic disease
 Yes 41 (40.6%) 5 (22.7%)
 No 37 (36.6) 13 (56.6%)
 Unknown 23 (22.8%) 4 (18.2%)
Age at onset (years) median (range) 2.8 (0–17.2) 4.45 (0–14.29)
Age at transplant (years) median (range) 11.8 (2.6–20.8) 16.71 (4.56–31.1)
Time to ESRD (years) median (range) 3.3 (1.7–14.3) 2.5 (0–7.5)
Time on dialysis before transplantation (years) median 
(range)
2 (0–9) Not available
Donor type
 Living 6 (5.9%) 2 (9.1%)
 Deceased 95 (94.1%) 20 (90.9%)
Follow-up (months) median (range) 58.5 (0.7–157.8) 40 (0–148)
Table 2  Prevalence of mutations among patients with available genetic results
Gene Encoded protein Mode of inheritance Genetic 
tests 
n = 76
NPHS1 Nephrin Recessive 13
WT1 Wilms tumour protein Dominant 11
NPHS2 Podocin Recessive 8
ACTN4 α-Actinin Dominant 2
PLCE1 Phospholipase C Recessive 1
COL4A5 Type IV collagen α5 chain X-linked recessive 1
SMARCAL1 SWI/SNF-related, matrix-associated, actin-dependent regulator 
of chromatin, subfamily A-like protein 1
Recessive 1
LMX1B LIM homeobox transcription factor 1 β Dominant 1
COQ2 Coenzyme Q2 Recessive 1
Heterozygous carriers Recessive 8
No mutations 29
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disease recurrence was 59.5% in Group B (idiopathic SRNS) 
and 43.5% in Group C (unknown genetic status). No Group 
A (genetic SRNS) child experienced disease recurrence 
and this group was therefore excluded from further analysis 
(Table 3).
The difference in post-transplant disease recurrence 
between Group B and C, however, was not significant 
(p = 0.23). Risk factors for recurrence were evaluated in 
the remaining 60 patients (Group B and C). Overall, SRNS 
recurred in 32/60 (53.3%) non-genetic patients.
As all relapses except one (identified 10 years after trans-
plantation) occurred within 8 months from transplant, the 
analysis was made at 8 months of follow-up and included 
all evaluable patients (54 patients). Age at transplant was 
categorized as ≥ 9 years, following a ROC analysis identify-
ing it as the best cut-off for relapse prediction in our dataset 
(Fig. 2). Bivariate analysis was performed by Wilcoxon test 
for independent samples. Multivariate analysis was per-
formed by a logistic regression model.
At bivariate analysis, the following variable were signifi-
cantly associated to relapse:
– Age ≥ 9 years (p = 0.01823)
– At least one HLA AB match (p = 0.01752)
– At least one HLA DR match (p = 0.01763)
Gender, donor age and donor type (living or deceased) 
did not affect the risk of recurrence. Time to ESRD and 
duration of dialysis before transplant were not significantly 
associated with relapse; anyway, they were both longer in 
children with relapse (median = 4.6 vs 2.7 years, p = 0.2673 
and 2.4 vs 1.8 years, p = 0.06582, respectively).
We were not able to assess the role of different induction 
schedules, since all patients were homogeneously treated 
with basiliximab and immunosuppressive therapy. However, 
among the two patients treated with pre-transplantation PE, 
one experienced relapse the day after transplant.
Multivariate analysis included all the variables associated 
with recurrence at the bivariate analysis with a p value < 0.1 
(Table 4). Age at transplant > 9 years and HLA-AB match 
were the only independent risk factors for recurrence after 
transplant (p = 0.01017 and p = 0.02465, respectively). How-
ever, the best prediction model for relapse, characterized by 
the lowest residual deviance and lowest AIC, included also a 
longer duration of dialysis before transplant (Null deviance: 
68.029 on 49 degrees of freedom; Residual deviance: 49.584 
on 46 degrees of freedom; AIC: 57.584; p = 0.06994). The 
model including the aforementioned 3 variables has a likeli-
hood ratio test p value of 0.000356, and a pseudo R squared 
value of 0.271136 (McFadden method).
The risk factors for recurrence in Group B and C are sum-
marized in Table 5.
Disease recurrence was treated in all patients with PE 
with a median of 20 sessions (range 4–79). 22 were treated 
with rituximab and 9 with high dose steroids. The use of 
other therapeutic agents was as follows: ofatumumab (3), 
mesenchymal stromal cells (2), intravenous immunoglobu-
lins (2), abatacept (2), cyclophosphamide (2), cyclosporin 
(1) and thymoglobulin (1). Overall, a complete or partial 
remission was achieved in 15 and 4 patients, respectively, 13 
patients (40.6%) failed to achieve sustained disease remis-
sion, despite treatment and 11/13 subsequently lost the graft. 
Use of rituximab or high dose steroids did not influence 
the response rate (p = 0.3574). The remission was persistent 
with preserved renal function in 13/15 patients. One patient 
Table 3  Incidence of recurrence, stratified by genetic testing results




Genetic results n, %
 Negative 37 22 (59.5) 15 (40.5)
 Unknown 23 10 (43.5) 13 (57.5)
 Positive 41 0 (0.0) 41 (100.0)
Fig. 2  ROC curve identifying the best cut-off for age at transplant 
with FPR = 0.58333333, TPR (sensitivity) = 0.86666667, Specific-
ity = 0.41666667, p value = 0.01823
Table 4  Variables included in the multivariate analysis
Variables
Age ≥ 9 years
At least one HLA AB match
At least one HLA DR match
Duration of dialysis before transplant
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had second untreatable relapse 10 years after transplant and 
lost the kidney. One additional patient with partial remis-
sion, following experienced rejection and lost his graft.
Graft loss
24 patients (23.8%) experienced loss of a first renal graft. 
The causes of graft loss were as follows: disease recurrence 
in 12 (50%), rejection in 6 (25%), primary non-functioning 
graft in 3 (12.5%), thrombosis in 2 (8.3%) and chemotherapy 
toxicity for post-transplant thrombo-proliferative disease in 
one case (4.1%). In addition, death with a functional graft 
due to sepsis occurred in two patients.
Second renal transplant
During the study period, 22 SRNS patients received a sec-
ond renal graft; 11 of them had had a recurrence in the first 
graft, while 11 lost their transplant for different reasons. 
Among patients with a previous recurrence, 2/11 patients 
lost their graft immediately after the transplantation for rea-
sons different from relapse (death and surgery complica-
tions) and were not included in the following analysis. After 
a median follow-up of 40 months, five patients relapsed on 
the second transplant. All of them have had a recurrence 
in the first graft. Therefore, in our population, only 5 out 
9 (55.5%) evaluable patients with a previous relapse expe-
rienced recurrence of proteinuria after the second kidney 
transplantation. Among five relapsed patients, only two 
subsequently lost the second graft. None of the 11 patients 
who lost the first transplant for different reasons suffered of 
relapse, with 4/11 having a genetic disease. Outside SRNS 
recurrence, two patients experienced a graft rejection and 
lost the second kidney graft and one patient died after a 
post-transplant lymphoproliferative disease.
Discussion
SRNS is a leading cause of ESRD in children. Post-trans-
plant recurrence is a common complication, associated with 
an increased risk of graft loss. Many efforts have been made 
to identify the risk factors for recurrence in order to improve 
prevention and treatment strategies [5, 6, 15].
Our study gives a clear picture of the Italian experience 
with kidney transplantation in children with SRNS, during a 
period of over 10 years, encompassing all the recent acqui-
sition regarding the etiopathology and therapeutic options 
for SRNS.
Table 5  Risk factors for post-transplant disease recurrence in Group B (idiopathic SRNS) and Group C (unknown genetic status) individuals, at 
8 months of follow-up
Statistically significant values in bold






 Male 30 (55.6%) 18 (60%) 12 (40%) 0.4624 0.26990
 Female 24 (44.4%) 12 (50%) 12 (50%)
Age at transplant, yr
 ≥ 9 40 (74.0%) 26 (65%) 14 (35%) 0.01823 0.01017
 < 9 14 (26.0%) 4 (28.6%) 10 (71.4%)
HLA-AB matching 0 vs > 0 0 vs > 0
 0 7 (13.5%) 1 (14.3%) 6 (65.7%) 0.01752 0.02465
 1 18 (34.6%) 13 (72.2%) 5 (27.8%)
 2 17 (32.7%) 9 (52.9%) 8 (47.1%)
 3 10 (19.2%) 6 (60%) 4 (40%)
HLA-DR matching
 0 16 (30.8%) 5 (31.2%) 11 (68.8%) 0.01763 0.46309
 1 34 (65.4%) 24 (70.6%) 10 (29.4%)
 2 2 (3.8%) 0 (0%) 2 (100%)
Recurrence No recurrence
Duration of dialysis median, range 2.4, 0.6–9 1.8, 0.1–5 0.06582 0.06994
Time to ESRD median, range 4.6, 0–12 2.7, 0–13 0.2673 0.72323
Donor age median, range 14, 1–63 11, 1–56 0.1609 0.84874
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The overall incidence of post-transplant disease recur-
rence (53% of non-genetic patients) is consistent with the 
available scientific literature, stretching back almost three 
decades [16, 17]. Recurrence is confirmed to be a very early 
event, with a median time from transplant of 2 days and 
30/32 events occurring within the first 2 months after trans-
plantation. By stratifying the cohort according to genetic 
status, we have been able to confirm that genetic SRNS 
does not recur after transplant. While previous reports have 
identified the genetic status as an important risk factor for 
disease recurrence, most available retrospective studies are 
unable to account for the genetic status of the majority of 
their cohorts [17, 18]. To the best of our knowledge, no 
previous studies were able to assess the risk of recurrence 
in an equally characterized population, as regards genetic 
disease. In our study, genetic results were indeed available 
for 76/101 patients (75.2%), furthermore since the remain-
ing individuals (Group C, unknown genetic status) closely 
resemble Group B (Idiopathic SRNS) in key clinical fea-
tures, including similar age of onset and rate of recurrence 
(43.5%), it is likely that most of them also represent cases of 
idiopathic SRNS. Indeed, we believe that patients with early 
onset or congenital SRNS were more likely to be tested for 
a genetic disease, while genetic testing was less performed 
in older children and adolescents with a clinical picture of 
idiopathic SRNS.
Our observation is in line with previous studies that 
report no or very low relapse rate after transplantation in 
children with genetic SRNS [9, 17, 19]. Few old reports 
have suggested a risk of relapse for genetic SRNS, but they 
are almost all related to NPHS2 mutation, including het-
erozygous individuals [20–23]. The causative role of the 
variants included in these reports should be reconsidered, as 
exquisitely suggested in a recent review by Bierzynska [15].
The rate of recurrence in idiopathic SRNS (Group B) 
was 59.5%. The result is slightly superior than previously 
reported. When genetic patients are excluded, Ding [17] and 
Pelletier [19] found a relapse rate of 46.3% and 47%, respec-
tively. The lower recurrence rate described by these groups 
could be justified by the presence of unknown genetic SRNS 
patients. Indeed, when both Group B and C are considered, 
the overall rate of recurrence was 53.3% in our cohort. 
Therefore, our data underline the importance of a genetic 
evaluation for SRNS genes in order to plan transplantation, 
as it represents the principle risk factor for recurrence.
Aside from absence of a genetic aetiology, our study iden-
tified age at transplant greater than 9 years and HLA-AB 
match as independent risk factors for recurrence. The best 
prediction model for recurrence included also a longer dura-
tion of dialysis.
Nehus et al. reported a higher rate of recurrence in 
younger children, among a cohort of 327 patients, though 
genetic results were not reported for any participants [24]. 
No significant difference in relapse rate according to the 
age at transplant were detected by Tejani and Stablein [12] 
and in the more recent studies by Ding et al. and Pelletier 
et al. [17, 19]. Again, unavailability of genetic testing for 
the majority of their patients could justify the different 
findings.
HLA-AB match was independently related to recurrence 
in our cohort, in contrast HLA AB or DR match did not 
influence the risk of relapse in the study by Tejani et al. 
[12] and did not affect transplant outcome in adolescent with 
SRNS in a retrospective study of the NAPRTCS registry 
[25].
Following the evidence that a circulating factor is respon-
sible for recurrence, it has been suggested that a prolonged 
dialysis prior to renal transplantation would have a protective 
effect as far as the risk of relapse is concerned. The results 
of our study do not support this hypothesis. Indeed, in our 
study cohort, a longer duration of dialysis was associated 
with an increased risk of relapse. Even if this variable did 
not reach significance, its inclusion identifies the best pre-
diction model for recurrence  (R2 0.271136). Among the few 
studies which investigated the association between duration 
of dialysis and disease recurrence, no significant differences 
were found in a single centre experience of 43 patients by 
Senggutuvan [16]. In a larger cohort of 132 paediatric renal 
transplants, found no relationship between disease recur-
rence and duration of dialysis was found [12]. Hence, since 
no protective effect was proven by others and our data show 
a longer duration of dialysis in patients with recurrence, even 
if not statistically significant, it is not justified to prolong 
the duration of dialysis before transplantation in children 
with SRNS.
Whether donor type (living vs deceased) is significantly 
associated with disease recurrence remains controversial. 
Data from old registries [26, 27] found no increased recur-
rence rates according to the type of donors. Other studies 
have suggested living donor as an independent risk factor 
for recurrence [17, 28, 29]. Our study cohort included only 
six living donor recipients (5.9%), reflecting the reluctance 
of paediatric nephrologists to use living donors in SRNS 
patients, due to the risk of recurrence and graft loss. On 
the other hand, since in our cohort no relapses occurred in 
genetic SRNS, another important clinical implication of 
our study is that living kidney donors can be safely used in 
genetic SRNS patients.
All patients from our cohort were treated with PE, fol-
lowing SRNS recurrence. Complete or partial remission was 
achieved in 19/32 (59.4%) children, with a functioning graft 
after a median follow-up of 39.5 months. Similar rates of 
response were previously reported. Kashgary et al. in their 
meta-analysis identified a remission rate of 70.2% in children 
treated with PE [14]. A lower response rate was reported by 
Pelletier [19], but remission information was available only 
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for 49/64 (77%) relapsed patients and the detailed immuno-
suppressive strategy is missing. According to our results, PE 
is confirmed as an effective treatment for recurrence. Even 
the small numbers, rituximab and high dose steroids did not 
influence the response rate in our cohort.
On the other hand, disease recurrence was the leading 
cause of graft loss in non-genetic SRNS and the rate of graft 
loss after relapse (34.3%) in our study is consistent with 
previous data [26].
Among the small number of retransplanted individuals 
included in our study, the overall incidence of relapse in a 
second renal graft after a first recurrence is not significantly 
different from the first transplant (55%). In 4/9 patients who 
experienced a relapse in their first transplant, proteinuria 
did not recur after the second transplantation. This contrasts 
with reported small cohorts in whom the incidence of recur-
rence approaches 100% once the first transplant was lost for 
recurrent SRNS [10, 12, 28, 30]. We are not able to identify 
the factors responsible of the different outcome, but accord-
ing to our data retransplantation after relapse can be consid-
ered in children with SRNS.
Conclusions
Twelve years of the Italian experience with post-transplant 
SRNS recurrence allows us to reach different important con-
clusions. Firstly, the absence of underlying genetic mutations 
predicts a high risk of post-transplant recurrence, therefore 
genetic screening must be performed in all children with 
SRNS before transplantation in order to best plan their care 
in the post-transplant period. Age > 9 years is an independ-
ent risk factor for recurrence, while a prolonged time spent 
on dialysis before transplantation has no protective effect 
on the risk of relapse and should not be encouraged. Living 
donor did not influence the risk of relapse and can be safely 
used in genetic SRNS patients. PE based treatment strategies 
are effective in the majority of relapsed patients. Finally, in 
those who experience graft loss, even for recurrence, it is 
appropriate to consider retransplantation, as it maybe cura-
tive in the long term.
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